XLV:NYSEARCA
State Street Health Care Select Sector SPDR ETF
$169.38
arrow_downward
-0.30%(-0.51) 1D
Sep 23, 10:58:12 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for XLV...
Open
$170.00
High
$171.02
Low
$169.28
Mkt. cap
1.09T
Avg. vol.
7.67M
Volume
588.10K
52-wk high
$176.60
52-wk low
$133.73
Open
$170.00
High
$171.02
Low
$169.28
Mkt. cap
1.09T
Avg. vol.
7.67M
Volume
588.10K
52-wk high
$176.60
52-wk low
$133.73
Related assets
News stories
From web sources and news partners
Fierce Pharma
·
4 minutes ago
Eli Lilly CEO touts 70% share as Medicare GLP-1 program reaches 700K seniors
Funds Society
·
1 hour ago
State Street SPDR UC Investments ETF launches
MarketBeat
·
1 hour ago
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
Simply Wall Street
·
2 hours ago
Twist Bioscience (TWST) Joins Lilly TuneLab, Is The Stock Fully Priced?
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia